Ethosuximide

Breastfeeding
  • TRADE NAMES: Emeside; Ethymal; Petnidan; Pyknolepsinum; Simatin; Zarondan; Zarontin (Pfizer)
  • INDICATIONS: Absence (petit mal) seizures
  • CLASS: Antiepileptic; succinimide
  • HALF-LIFE: 50–60 hours

Cases of birth defects have been reported with ethosuximide

Our database has 28 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTHER.


Page last updated 11/23/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top